Back to dashboard
All PlansCoverageLow impact

Genotype-Guided Tamoxifen Treatment

Blue Cross & Blue Shield of Mississippi·MS · Oncology, OB-GYN, Internal Medicine +1 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This policy confirms that CYP2D6 genetic testing to guide tamoxifen treatment remains investigational and not covered. The policy description was updated but the coverage decision remains unchanged - genotype-guided tamoxifen treatment is still considered investigational.

Action Required

Action needed
No immediate action required. Continue to deny claims for CYP2D6 genetic testing related to tamoxifen treatment as investigational. Ensure billing team is aware that these codes are not covered for this indication.

Affected Billing Codes

81226

Related policy hubs